Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNS-101 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT05864144Phase 2Completed
- Sponsor
- Sensei Biotherapeutics
- Start
- May 2023
- Primary completion
- Jun 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of solnerstotug in solid tumor, colorectal cancer (CRC), head and neck cancer (HNC) and 2 more (3 arms), sponsored by Sensei Biotherapeutics. Primary endpoints: Adverse Events, Recommended Phase 2 dose or maximum tolerated dose and 1 more. Started May 2023; status: completed.
02
Drugs
solnerstotug
03
Conditions
solid tumorcolorectal cancer (CRC)head and neck cancer (HNC)melanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05864144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05864144.